Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ACP1 | P24666 | 5/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977925 | 0.92 | EGFR (0.52) | EGFRACP1BCHEMEN1KMT2A | |
| SCHEMBL24732635 | 0.87 | ACP1 (0.47) | EGFRACP1BCHEACHECYP1A2 | |
| SCHEMBL30947350 | 0.87 | ACP1 (0.47) | EGFRACP1BCHEACHECYP1A2 | |
| SCHEMBL30947362 | 0.85 | EGFR (0.52) | EGFRACP1BCHECYP1A2CYP3A4 | |
| SCHEMBL30947363 | 0.85 | EGFR (0.52) | EGFRACP1BCHECYP1A2CYP3A4 | |
| SCHEMBL29809293 | 0.82 | EGFR (0.46) | EGFRACP1BCHEACHECYP1A2 | |
| SCHEMBL24732840 | 0.82 | EGFR (0.46) | EGFRACP1BCHEACHECYP1A2 | |
| SCHEMBL30947336 | 0.80 | EGFR (0.45) | EGFRACP1BCHEALDH1A1MAPT | |
| SCHEMBL24733058 | 0.79 | ACP1 (0.49) | EGFRACP1BCHEACHECYP1A2 | |
| SCHEMBL29977635 | 0.79 | ACP1 (0.49) | EGFRACP1BCHEACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | EGFR 2553/4885ACP1 3773/4885BCHE 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.